TCTAP 2012 Late Breaking Clinical Trials

Main Session 3, Main Arena, Level B2, 9:30 AM - 10:30 AM

VARC Outcomes Following TAVI with Both Edwards SAPIEN™ and Medtronic CoreValve ReValving System® Devices: 30-Days and One-Year Results from the Milan Registry

Alaide Chieffo, MD

The aim of this study was to assess clinical outcomes following transcatheter aortic valve implantation (TAVI) according to the Valve Academic Research Consortium (VARC) definitions in our single center experience. In total, 400 consecutive patients with severe symptomatic aortic stenosis underwent TAVI in the San Raffaele Scientific Institute, Milan, Italy from Nov. 2007 to Feb. 2012 utilizing either Edwards SAPIEN™/SAPIEN XT™ or Medtronic CoreValve ReValving System® devices, since they were commercially available in Europe. The overall mean age was 79.4 ± 7.4 years, logistic EuroSCORE 24.0 ± 17.0% and STS score was 8.7 ± 8.4%. In the majority of cases (n=313; 83.3%), the transfemoral access site was used. Thirty-day mortality was 4.7%, myocardial infarction 1.3% and stroke 1.0%, life-threatening bleeding occurred in 22.7% and 13.5% had a major vascular complication. The median clinical follow-up length was 363.0 (IQR 185.5-530.0) days. At one-year, all-cause mortality was 13.5% and cardiovascular mortality 7.9%.

A further sub-analysis was performed in the transfemoral population in those patients undergoing new generation SAPIEN XT™ implantation (n=141) vs. CoreValve® (n=92). No difference between SAPIEN XT™ and CoreValve® was observed at 30-days in all-cause mortality (respectively 3.1% vs. 6.7%; p=0.2) or in the freedom from the combined safety endpoint (75.4% vs. 72.2%; p=0.597). However, there was a significantly higher device success amongst the SAPIEN XT™ group (97.1% vs. 89.1%; p=0.012), mostly as a consequence of the lower need for a second valve (1.4% vs. 7.6%; p=0.018). Furthermore, there were significantly less conduction disturbances/arrhythmia (17.3% vs. 34.8%; p=0.002) as well as pacemaker implantation (5.1% vs. 31.5%; p=0.001).

In this single center experience, TAVI appeared relatively safe and effective in patients with severe symptomatic aortic stenosis considered high-risk for surgical aortic valve replacement, with a low mortality rate at 30-days and one-year follow-up and acceptable outcomes according to VARC definitions. With SAPIEN XT™ there was a lower incidence of arrhythmia and pacemaker implantation and higher device success.

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Long-Term Effects of Varying Alcohol Dosing

Josef Veselka, MD

The idea of inducing a septal infarction by catheter techniques was suggested by the observation that myocardial function of selected areas of the left ventricle can be suppressed by balloon occlusion of the supplying artery during angioplasty. The outflow pressure gradient in hypertrophic obstructive cardiomyopathy (HOCM) decreased significantly when the first septal artery was temporarily occluded by an angioplasty balloon catheter. This concept was also supported by observations that the outflow pressure gradient decreased after anterior myocardial infarction in HOCM patients. Sigwart published his experience with alcohol injection into the septal branch (“non-surgical myocardial reduction”) of three patients with HOCM in 1995. Since then, several modifications of the original technique have...
PROMUS Element™ Plus
Everolimus-Eluting Platinum Chromium Coronary Stent System
is coming

Learn more at www.PtCr-stent.com.
During the first post-procedural year, 1 patient died from the low-dose group and 3 patients from the high-dose group died during the subsequent follow-up period (NS). There were no significant differences between the groups and all main changes occurred in the first post-procedural year. Time course of pressure gradient is summarized in the Figure below.

This study demonstrates that ASA treatment for HCM is safe and effective in the long-term. No differences were found between patients treated with low or high doses of alcohol with respect to the long-term efficacy and safety of ASA.

Long Term Clinical Outcomes in Patients Treated with the Resolute Zotarolimus-eluting Stent

Dr. Meredith will be presenting the data on long term clinical outcomes of the Resolute zotarolimus-eluting stent (R-ZES), which is a new generation drug-eluting stent comprised of a cobalt-alloy bare metal stent and durable polymer. The RESOLUTE Clinical program is a set of 5 trials (1 randomized and 4 single arm) evaluating the R-ZES in 5,130 patients, prospectively designed with similar procedures including: data collection forms and procedures, adverse event definitions and adjudication procedures, statistical programming algorithms, and data sets. Patient-level data were pooled to compare long-term safety and efficacy of the R-ZES with another contemporary drug-eluting stent.

They used propensity scoring, calculated from 32 covariates, to adjust for differences in baseline characteristics for comparisons between the R-ZES and the everolimus-eluting stent (EES) arm of the RESOLUTE All Comers trial. Additional analysis was performed to also adjust for duration of antiplatelet therapy.

The following studies (N, longest follow-up) contributed to patients being treated with the R-ZES: the RESOLUTE first-in-human study (N = 139, 5 years); the randomised RESOLUTE All Comers, non-inferiority trial, comparing R-ZES (N = 1140) with the XIENCE V EES (N=1152, 2 years). With 2-year follow-up completed for 3628/5130 (70.7%) patients from 3 of the 5 studies, the cumulative incidence of target lesion failure was R-ZES: 9.4% vs EES, 10.7%, p=0.40; cardiac death: 2.4% vs 2.2%, p= 0.70; target-vessel myocardial infarction: 3.4% vs 4.5%, p=0.51; ischemia-driven target lesion revascularization: 4.8% vs 5.2%, p=0.98 and ARC definite and probable stent thrombosis: 0.96% vs 0.98%, p=0.32.

In addition, the adjusted risk for adverse events was comparable between the R-ZES and the EES for the subset of patients who have completed the 2-year follow-up. You will get further information in this presentation.
FFR Guided and IVUS Supported Functional Angioplasty in Left Main Coronary Artery Disease

In this TCTAP 2012 meeting, Seung-Jung Park, MD from Asan Medical Center, Seoul, Korea summarized the concept of optimal treatment of left main coronary artery disease: FFR guided and IVUS Supported Functional Angioplasty in Left Main Coronary Artery Disease. Significant narrowing of the left main coronary artery puts a patient at high risk, since it can jeopardize the entire myocardium of the left ventricle, and it has the worst prognosis of any form of coronary artery disease. Therefore, for several decades, based on clinical trials for comparing coronary-artery bypass grafting (CABG) with medical therapy, bypass surgery has been regarded as the treatment of choice for patients with unprotected left main coronary artery (LMCA) disease. However, recently, marked advancements in techniques of percutaneous coronary intervention (PCI) and adjuvant pharmacologic therapy make a new evaluation of the optimal revascularization therapy for LMCA disease. In fact, several clinical trials and large off-label experiences demonstrated that stenting yields mortality and morbidity rates that compare favorably with CABG, which allows PCI to receive a class I indication for the treatment of LMCA stenosis in the current guideline update. Therefore, SJ Park said “now is the time to discuss how to optimize the PCI results moving away from the long-standing debate about the feasibility and safety of LMCA stenting.”

First, identification of a significant stenosis in LMCA is of critical prognostic importance. Traditionally, angiographic diameter stenosis of 50% has been considered as a cut-off for significant LMCA stenosis. The conventional coronary angiogram, however, has limitations in assessing lesion morphology and the true luminal size of the LMCA. Recently, SJ Park presented that reverse mismatch (insignificant angiographic stenosis but reduced FFR) was more frequent in LMCA as compared with non-LM epicardial artery, mainly due to the large myocardial burden (Figure 1). Therefore, FFR measurement should be performed for the LMCA evaluation, particularly when significant LMCA stenosis is clinically suspected. Several studies demonstrated that the FFR guided decision of making the treatment of LMCA associated with favorable prognosis and the intermediate LMCA with FFR≥0.75-0.80 could be safely deferred. In an evaluation of 213 patients with intermediate LMCA stenosis, the 138 patients with FFR ≥0.80 were treated medically, whereas the 75 patients with FFR <0.80 underwent coronary artery bypass grafting. Their 5-year survival rates were 89.8% and 85.4%, respectively (P=0.48). In a trial of 54 patients with angiographically intermediate LMCA, those with FFR≥0.75 (n=24) received medical treatment, whereas those with FFR<0.75 (n=30) underwent surgical revascularization. The survival rates at 3 years were 100% and 97%, respectively, and the event-free survival rates were 76% and 83%, respectively. In a study of 142 patients with LMCA stenosis, those with FFR≥0.80 (n=82) were treated medically, whereas those with FFR<0.75 (n=60) underwent coronary revascularization (6 underwent PCI and 54 underwent bypass surgery). During a follow-up of 14±11 months, the rates of cardiac death or MI were 6% and 7%, respectively (P=0.70). In a study of 51 patients with suspected LMCA stenosis, surgical revascularization was performed if FFR was <0.75 along the left main stem, whereas medical treatment was administered if FFR was ≥0.80 or if PCI was required elsewhere in the coronary tree; if FFR was ≥0.75 but ≤0.80, treatment depended on additional individual criteria. Estimated survival after 4 years of follow-up was 81% among patients in the surgical treatment group and 100% among patients in the medical treatment group. An investigation of 55 patients with ambiguous LMCA stenosis, 14 with FFR<0.75 and 41 with FFR≥0.75, found that the 38 month survival rates were 100% in both groups. However, FFR measurements in patients with LMCA stenosis should be interpreted with caution because isolated LMCA stenosis is very rare with most associated with disease in the left anterior descending artery and/or left circumflex artery, both of which tend to increase FFR measured across the LMCA stenosis. Therefore, the functional significance of LMCA stenosis should be reassessed following the correction of distal coronary artery stenosis. In addition, because of the potential for the guiding catheter to obstruct blood flow across the LMCA stenosis, FFR measurements should be performed with the guiding catheter disengaged from the coronary ostium and with hyperemia induced by intravenous adenosine.

IVUS can complement the limitation of FFR measurement in LMCA disease because of the high positive predictive value of IVUS minimal lumen area in LMCA stenosis. We evaluated the correlation of the FFR and IVUS MLA and found that the best predicted an FFR<0.80 was IVUS measured MLA 4.5mm² (83% sensitivity, 83% specificity, 83% accuracy, AUC=0.89, 95% CI=0.759–0.960, p<0.001). Of interest is that positive predictive value of IVUS measured MLA>4.5mm² is acceptably high by 83%, in contrast with the non-LMCA stenosis. In the meantime, SJ Park evaluated the optimal IVUS-MSA criteria to prevent ISR in 403 patients undergoing sirolimus-eluting stent implantation for LMCA disease. The best IVUS-MSA criteria that predicted angiographic ISR on a segmental basis were 5.0mm² for the LAD ostium, 6.3 mm² for the LAD ostium, 7.2 mm² for the POC, and 8.2 mm² for the proximal LMCA above the POC (Figure 2). SJ Park also published the importance of IVUS surveillance in LMCA stenosis. In the MAIN-COMPARE registry, patients with unprotected LMCA stenosis who underwent PCI under the guidance of IVUS (756 patients) were compared with those who underwent PCI under the guidance of conventional angiography (219 patients). The 3-year outcomes between 2 groups showed that a tendency of lower risk of 3-year mortality with IVUS guidance in the overall population; particularly, in patients who underwent the implantation of drug-eluting stent, the use of IVUS guidance reduced the 3-year incidence of mortality (4.7% vs. 16.0%, long-rank p=0.048).

SJ Park concluded that FFR guided complex PCI, which was supported by IVUS, can help us better to understand complex anatomical disease and may improve the clinical outcomes of complex LMCA disease.
TCTAP Session & Featured Lectures

Main Arena, Vista Hall, Level B2, 10:10 AM, 11:09 AM

The Use, Abuse and Value of Platelet Reactivity Testing During Complex PCI

Sorin Brener, MD

It has been well known that platelet inhibition varies substantially in patients treated with clopidogrel and high residual platelet activity is associated with a higher rate of ischemic events than lower platelet reactivity. Up-to-date knowledge about platelet function test and its implications in clinical practice will be presented at the Main Arena, Vista Hall (Level B2), April 25, at 10:10 am by Sorin Brener.

Numerous tools for platelet function test have been developed in recent years. Through the test we realized that there are significant variations in the response to antiplatelet agents, most of them to clopidogrel. Several studies have shown that the platelet function assessed by the VerifyNow Analysis is clearly related to post-PCI ischemic risk (Brar SS, et al. JACC 2011;58:1945). To date, GRAVITAS and TRIGGER-PCI studies have been completed and those outcomes will be shown in this session.

Genetic mutations play a big role in the variations. The newer generation antiplatelet agents including prasugrel, ticagrelor and cangrelor could get over the variations in response to clopidogrel. Furthermore, those new agents are known to be more potent than clopidogrel. In general, the more the platelet function is suppressed, the better the clinical outcomes are. However, bleeding risk increases when the platelet function is suppressed even below a certain threshold. In that point, the platelet function test may be useful in clinical practice.

The general consensus on this issue was the following platelet function testing may be considered in patients at high risk for poor clinical outcomes. In clopidogrel-treated patients with high platelet reactivity, alternative agents, such as prasugrel or ticagrelor, might be considered. The routine clinical use of platelet function testing to screen clopidogrel-treated patients undergoing PCI is not recommended.

Complications after TAVR: Frequency and Clinical Importance

Martin B. Leon, MD

Nov. 2, 2011, The FDA approval of the first transcatheter aortic valve for replacing a native valve damaged by severe aortic stenosis marks an exciting time in the field of interventional cardiology. However, it is important to step back and examine potential complications of this relatively new technique. These issues will be discussed at the Main Arena, Vista Hall (Level B2), April 25, at 11:09 am by Martin B. Leon.

With regards to transcatheter aortic valve replacement (TAVR), recent growth has been phenomenal. Estimates from Europe, for example, indicate that the number of TAVR procedures performed there in 2001 will exceed 17,500. Leon (New York-Presbyterian Hospital, Columbia University Medical Center) and colleagues initiated the Valve Academic Research Consortium, also known as VARC, to identify the most relevant clinical endpoints and endpoint definitions in response to a tidal wave of uncontrolled TAVR clinical trials. Several groups reviewed the literature and completed a study-level meta-analysis of more than 3,500 patients from 17 studies. Most patients were older (mean age, 81 years) and female.

Stroke definition and ascertainment are highly variable in surgical aortic valve replacement (AVR) and TAVR literature. Stroke frequency is increased after TAVR - about two to three times compared with AVR - and the difference is an early peaking hazard, and appears largely due to ischemic embolic events. Transcranial doppler studies suggest that native valve manipulation may be an important contributor to early stroke. Cerebral embolic protection and increased pharmacotherapy are currently under investigation. Although there is much to learn about stroke and TAVR, it is not an unmanageable complication.

Vascular complications after TAVR, including hematoma dissection and perforation are frequent and have been associated with increased mortality. Vessel-sheath size ratio, calcification and center experience appear to be important predictors. Meticulous CTA screening, site/operator experience, reduced caliper devices and dedicated access site closure systems will improve future outcomes. Paravalvular leak after TAVR occurs frequently in up to 80% of patients. However definitions and grading of paravalvular severity remain inconsistent and problematic. Causes and predictors of paravalvular leak are multifactorial, and may include optimal valve sizing, calcification and valve position. Operator experience and post-dilatation have been associated with reduced paravalvular leak. Significant paravalvular leak has been a predictor of subsequent mortality, although observation is limited. New TAVR designs may reduce paravalvular leak in the future.

The need for permanent pacemakers after TAVR is an important complication that requires more intense and prolonged inpatient monitoring and exposes patients to lifelong hazards. The threshold for needing a permanent pacemaker after TAVR is extremely variable and better guidelines are required. In the future, improved implantation techniques and modified TAVR systems will reduce the rates of permanent pacemakers after TAVR to levels similar to surgical AVR. Short and mid-term TAVR system durability appears encouraging, with infrequent endocarditis, maintained hemodynamic performance and no other signs of structural valve deterioration. However, several caveats exist, including a lack of long-term data and unknown imponderables such as late effects on coronary arteries and the mitral valve.

‘Master of the Masters’

Dr. Martin B. Leon, director of Center for Interventional Vascular Therapy, Columbia University Medical Center / New York-Presbyterian Hospital, was recognized as the 2nd recipient of TCTAP Award ‘Master of the Masters’, held on April 25 (Wed) at the Main Arena (Vista hall), the convention center of Sheraton Grand Walkerhill hotel.

CardioVascular Research Foundation (CVRF), organizing committee of ANGIOPLASTY SUMMIT-TCTAP has held an award ‘Master of the Masters’ during TCTAP since 2011 and Dr. Masakito Nobuyoshi, director of Kokura Memorial Hospital, was honored as the 1st recipient of this award last year. TCTAP Award ‘Master of the Masters’ is bestowed to honor and show appreciation to outstanding teachers and dedicators in the field of interventional cardiology. Especially TCTAP has been benefited from Dr. Leon’s outstanding expertise and value enabling this meeting more special. Therefore, the organizing committee has generously agreed to nominate him to this award.

Dr. Leon is the founder of Cardiovascular Research Foundation (CRF) and course director of the world-renowned TCT conference in the US. He has contributed significantly to the interventional cardiology not only in US, but also internationally through this conference. Furthermore, he has exerted further efforts to develop the intervention field in Asia-Pacific through the collaboration between CRF and ANGIOPLASTY SUMMIT-TCTAP. His unassuming and quiet manners hold a long list of achievements, contributions and long-standing meritorious service to the medical community accomplished over a period of more than two decades. The 3rd TCTAP Award will be held at the next year’s meeting. Who will be the next master?
XIENCE PRIME is built on XIENCE V DES technology.


All drawings are artist’s representations only and should not be considered as engineering drawings or photographs.

Information contained herein for Outside US and Japan ONLY. Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

This product is intended for use by or under the direction of a physician. Prior to use, it is important to read the package insert thoroughly for instructions for use, warnings and potential complications associated with the use of this device.

XIENCE V and XIENCE PRIME are trademarks of the Abbott Group of Companies.

For more information, visit our website at www.XiencePrime.com

© 2012 Abbott Vascular. All rights reserved. KR00001SRevA03/12
LESS RISK... MORE CONFIDENCE*

LEADERS

4-YEAR RESULTS

4-year results from the LEADERS study, a head-to-head randomized trial between BioMatrix Flex™ and a durable polymer sirolimus-eluting stent in an "all comers" patient population, were published in The Lancet in December 2011:

1. See The Lancet publication on-line. 1

2. See presentation on-line. 2

---

* Based on LEADERS results on MACE, definite VSTL and cardiac events associated with dissection and thrombus formation.
NEW

PREDICTABLE RESPONSE\(^2\) & SUPERIOR PROTECTION AGAINST THROMBOTIC CV EVENTS VS. Clopidogrel\(^3\)

Effient\(^2\) tablet 5mg/10mg (Prasugrel HCL)

---

References: [Details provided in the document]

Lilly Korea Ltd. 4th Floor, STX Naman Tower, Namdamunro 5-ga, Jung-gu, Seoul, Korea 100-958. Tel. +82-02-3459-2676

Daiichi Sankyo Korea Co., Ltd. West Building 3rd Floor, POSCO Center, Deochi 4-dong, Gangnam-gu, Seoul, Korea 135-777. Tel. +82-02-3453-3305
STICH (the Surgical Treatment of Ischemic Heart Failure) trial is the largest randomized, controlled study ever to compare CABG plus the best possible medical therapy to aggressive medical therapy alone in patients with coronary artery disease and heart failure. In the main STICH study, for which 1,212 patients with ischemic LV dysfunction and an EF of 35% or less were enrolled, no significant all-cause mortality differences were observed by intention-to-treat analysis between patients undergoing coronary artery bypass grafting (CABG), compared with optimal medical therapy. In the CABG group, however, the prespecified secondary endpoint of cardiovascular death—that is, the mortality outcome more likely to be influenced by CABG—was reduced by 19% with borderline statistical significance (P=0.05) whereas the composite endpoint of cardiac death and hospitalization for cardiac cause was significantly reduced by 26%. Interestingly, a significant 30% all-cause mortality reduction was observed in the CABG group in the as-treated analysis, which took into account the substantial crossover rate (17%) of patients assigned to medical therapy who underwent CABG, pointing to the possibility that such crossover may have diluted the benefit of CABG in the primary intention-to-treat analysis. Therefore, as acknowledged by the authors, the results of the STICH study do not definitively deny the advantage of CABG in LV dysfunction but rather provide, from secondary analysis, provisional evidence in favor of revascularization in ischemic LV dysfunction.

A viability STICH substudy evaluated whether imaging could be used to identify which patients are likely to benefit from bypass surgery. Researchers recruited a total of 601 patients to have one of two types of imaging tests: a nuclear perfusion scan or dobutamine echocardiography. The results of that study showed that survival of patients with viability was significantly longer than that of patients without viability, but patients with viable myocardium undergoing CABG did not show survival benefit compared with those treated with optimized medical therapy. The study results thus disputed the conclusion of the previous metaanalysis and questioned the recommendations of guidelines for viability-guided treatment in patients with ischemic LV dysfunction.

Breakfast Meeting: STICH or Not STICH

Tutorial Arena, Level 4, 7:00 AM – 8:10 AM

Antiplatelet therapy is a first-line medical treatment for patients with any clinical manifestation of coronary disease. As percutaneous coronary interventions (PCI) increase in number and complexity, more patients must be treated with antiplatelet therapy for cardiovascular diseases in which arterial thrombosis plays a major role, including double or even triple antiplatelet regimens after stent implantation. Nevertheless, a significant number of patients continue to experience recurrent complications despite being properly treated, due to some reasons: pharmacokinetics and interactions of drugs, genetic background and increased thrombus formation. New antiplatelet agents such as prasugrel or ticagrelor have been developed for patients at high risk of thrombosis. Prasugrel is an ADP-P2Y12 receptor inhibitor that has a faster and more consistent inhibitory effect of platelet aggregation. In the TRITON-TIMI 38 trial, prasugrel therapy was associated with less major adverse cardiac event occurrence than clopidogrel therapy in high-risk ACS patients undergoing PCI. The effect of prasugrel therapy on the occurrence of stent thrombosis was dramatic (about 50% reduction). There was also a significant increase in major non-CABG bleeding risk (32%), which persisted over the duration of treatment.

Ticagrelor is a direct-acting P2Y12 receptor blocker with some pharmacokinetic advantages over prasugrel and clopidogrel (mainly because is not a pro-drug and does not need hepatic transformation into an active metabolite and its reversible platelet inhibition). The PLATO study showed the superior clinical efficacy of ticagrelor. So their benefits in terms of mortality and major cardiovascular events have been demonstrated, but some concerns remain regarding the possible increase in bleeding. In addition, both high on–treatment platelet reactivity (HPR) and the cytochrome (CYP) P2C19 reduced function genotype are associated with a significant increase in ischemic risk in PCI patients treated with clopidogrel, and this is not surprising given the central role of the ADP-P2Y12 interaction in the genesis of coronary thrombosis. The recent 2011 American and European guidelines have given a class IIb recommendation for platelet function testing or genotyping if the results of testing may alter management. Several studies have been published that question the value of platelet function and genetic testing. Whether platelet function testing combined with genetic test–guided treatment might be a successful management strategy in high-risk ACS patients is being investigated in ongoing randomized trials. Until the results of these large-scale trials of personalized antiplatelet therapy are available, the routine use of platelet function assays or genotype testing in the care of patients with cardiovascular disease remains unproven.

Breakfast Meeting: Antiplatelet Therapy

Wednesday, April 25, Tutorial Arena, Level 4, 7:00 AM – 8:10 AM
Yesterday’s Hot lives

Transcatheter Aortic Valve Implantation with the CoreValve

Yesterday, Dr. Seung-Jung Park and Eberhard Grube demonstrated successful treatment with the CoreValve for severe AV stenosis. An 83 year-old female was admitted with dyspnea on exertion (NYHA class II) for about three months. She has a past medical history of diabetes, hypertension, and claudication. Her logistic EuroSCORE was 26.35%. Her coronary angiogram was normal. Transthoracic echocardiography showed very severe degenerative AV stenosis and severe concentric LVH with normal LV systolic function (EF=66%). AV area by continuity equation was 0.64 cm². Transaortic valve maximal velocity was 5.4 m/s. Mean and peak pressure gradient were 63 and 115 mmHg. Transesophageal echocardiography showed the opening limitation of AV because of heavy calcification and thickening (Figure 1). Her AV was tricuspid and annulus size by TEE was 21 mm (Figure 2). Annulus size by CT was 20-21 mm and perimeter was 81 mm (Figure 3). Distance from annulus to LM and RCA ostium was 14.7 and 15.2 mm, respectively. The right lowest diameter was 7.6mm and there was no problem in vessel size and calcification. Therefore, we chose the right approach. Although the annulus size by TEE and CT was 21 mm, perimeter was 81 mm. After discussion, we selected the larger sized CoreValve (29 mm). 6 Fr sheath and a temporary pacemaker were inserted through left femoral vein and 7 Fr sheath and 6 Fr pig-tail catheter were inserted through left femoral artery. After right peripheral angiogram with pig-tail catheter, we checked the proper puncture site of right femoral artery. 7 Fr sheath was inserted through right femoral artery and then three 8 Fr Proglide devices were placed into the right femoral artery. After removal of the sheath, 18 Fr Ultimam sheath was placed. Then an AL 1 diagnostic catheter with a stiff wire was used to cross the aortic valve. After crossing AV, the stiff wire was replaced by a super-stiff wire and then the 18 Fr CoreValve delivery catheter system (AccuTrak) was advanced gently into the vessel. The CoreValve crossed over AV using the super-stiff wire and deployment was done. After the CoreValve implantation, adjunctive balloon dilatation was done using a Tyshak II 25x40 mm. Final fluoroscopy showed a well-positioned CoreValve (Figure 4).

Left Main Ostial Lesion Treatment Using Simple Cross-Over Technique

Yesterday, Dr. Gregg W. Stone and Duk-Woo Park treated left main ostial lesion. A 76 year-old female was admitted with effort chest pain for about six months. Her coronary risk factor was hypertension. The physical examination was normal. The ECG and cardiac enzymes were unremarkable. Cardiac stress perfusion CT showed severe stenosis of LM ostium and decreased perfusion at LAD territory. Thallium test and treadmill test were not done. The left coronary angiogram showed discrete tight stenosis at left main ostium (Figure 1). An 8 Fr sheath was inserted through right femoral artery and the left coronary ostium was engaged with an 8Fr JL 4.0 catheter with side hole. Two 0.014 inch BMW wires were inserted into the LAD and LCX, respectively and then they performed intravascular ultrasound evaluation from LM to LAD. Without predilatation, they deployed an Xience-Prime stent 3.5x28 mm at the LM ostium. Thereafter, post-stenting adjunctive balloon dilatation was done using Dura Star 4.0x15 mm and Quantum 4.5x12 mm sequentially. Final angiogram showed a well-expanded and well-positioned stent (Figure 2).
FOR PATIENTS WITH
HYPERCHOLESTEROLEMIA

AN EFFECTIVE LDL-C TREATMENT,
FUELED BY DUAL POWER

This is HYBRID therapy

Product Information

VYTORIN tablets (Ezetimibe/Simvastatin 10/10, 10/20, 10/40, 10/80mg)

[Indications and Usage] VYTORIN is indicated as additive therapy to diet for the reduction of elevated total C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary heterozygous familial and nonfamilial hypercholesterolemia or mixed hyperlipidemia. VYTORIN is indicated for the reduction of elevated LDL-C and LDL-C in patients with homozgyous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. [Dosage and Administration] The patient should be placed on a standard blood-lowering diet before receiving VYTORIN and should continue on this diet during treatment with VYTORIN. VYTORIN should be taken as a single daily dose in the evening, with or without food. The recommended usual starting dose is 10/20 mg/day. Initiation of therapy with 10/20 mg/day may be considered for patients requiring less aggressive LDL-C reductions. [Contraindications] Hypersensitivity to any component of this medication, active liver disease, or unexplained persistent elevations in serum transaminases, pregnancy and lactation; patients with hereditary problems of galactose intolerance, Lapp lactase deficiency or of glucose-galactose malabsorption. [Warnings] Myopathy and rhabdomyolysis are known adverse reactions to HMG-CoA reductase inhibitors and other lipid-lowering drugs. Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase above 10 X ULN. Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. In three placebo-controlled, 12-week trials, the incidence of rhabdomyolysis among 1040 mg simvastatin was 0.4% of patients treated with VYTORIN and up to 0.3% with placebo. For patients treated with VYTORIN 10/80, in controlled long-term (48-week) extensions, which included both newly treated and previously treated patients, the incidence of rhabdomyolysis was 0.6% overall and 3.6% for patients treated with VYTORIN 10/80. These elevations in transaminases were generally asymptomatic, not associated with cholestasis, and returned to baseline after discontinuation of therapy or with continued treatment. It is recommended that liver function tests be performed before the initiation of treatment with VYTORIN, and thereafter when clinically indicated. Patients treated with the 10/20 mg dose should receive an additional test prior to titration, 3 months after titration to the 10/40 mg dose, and periodically thereafter (i.e., semiannually) for the first year of treatment. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormalities have returned to normal. Should an increase in AST or ALT of 5 X ULN or greater persist, withdrawal of therapy with VYTORIN is recommended. VYTORIN should be used with caution in patients who consume substantial quantities of alcohol and have a past history of liver disease. Active liver diseases or unexplained persistent transaminase elevations are contraindications to the use of VYTORIN. [Adverse Reactions] VYTORIN has been evaluated for safety in more than 3600 patients in clinical trials. VYTORIN was generally well tolerated. Clinical AE reported in >1% of patients treated with VYTORIN and ≤1% incidence greater than placebo regardless of causality assessment from three similarly designed, placebo-controlled trials were headache, influenza, upper respiratory tract infection, myalgia, pain in extremity. (Pregnancy/Nursing mother) Should not take VYTORIN. (Pediatric/Geriatric Use) There are insufficient data in pediatric patients. The safety of VYTORIN was similar between geriatric and younger patients. Greater sensitivity of some older individuals cannot be ruled out. [2011.12.19]

Before prescribing, see full prescribing information for VYTORIN.

Reference

MSD KOREA LTD.
Copypright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J. USA All Rights Reserved.
Left Main & Bifurcation Summit: "Paradigm Shift"

Coronary Session 2, Coronary Arena, Level 1, 8:30 AM - 11:18 AM

Left Main Summit

4-year Outcomes of SYNTAX Left Main

Dr. Patrick W. Semsys will be lecturing about "4-year Outcomes of SYNTAX Left Main", which was previously presented at TCT 2011 (San Francisco) in this Left Main Summit session. In the left main subset of SYNTAX trial, a total of 673 randomized patients (CABG=324 vs PCI=349) were followed for 4 years. At 4 years, major adverse cardiac and cerebrovascular events (MACCE: death, stroke, myocardial infarction (MI), and repeat revascularization) were analyzed. The result showed higher repeat revascularization rate in PCI group (PCI: 23.5% vs. CABG: 14.6%, P=0.003). However, rates of the composite safety endpoint (death/stroke/MI 17.1% vs. 17.7%, P=0.79) and stroke alone (1.5 vs. 4.3%, P=0.03) were not significantly different between treatment groups. In the low score (0-22) and intermediate score (23-33) group by SYNTAX Score, there were no significant differences about all endpoints (death/stroke/MI) between the two groups. But, when the SYNTAX Score was high (≥23), the rate of repeat revascularization was higher in PCI group (31.3% vs 11.8%, P=0.001). In conclusions, at 4 years, revascularization with PCI has comparable safety and efficacy outcomes to CABG and PCI is therefore a reasonable treatment alternative in this patient population, in particular, when the SYNTAX Score is low (<22) or intermediate(22-33) for patients with left main disease.

Outcomes of Left Main PCI with New Generation DES: PRECOMBAT-2 Study Using Everolimus-Eluting Stent

Dr. Young-Hak Kim of Asan Medical Center, Republic of Korea will present the outcomes of PRECOMBAT-2 study. Recent registries and randomized studies have shown that PCI is safe and effective in patients with unprotected left main coronary artery stenosis. In particular, the SYNTAX left main study and PRECOMBAT trials showed that PCI with sirolimus-eluting stents or paclitaxel-eluting stents was noninferior to CABG in terms of 1-year incidence of major adverse cardiac or cerebrovascular events. These results have led to recently updated recommendations that PCI may be considered an alternative to surgery in patients who are not at high risk. Nonetheless, PCI for left main stenosis, particularly with bifurcation involvement, remains technically challenging and is related to higher rates of stent thrombosis and repeat revascularization. As compared with first generation DES, the reduced strut thickness (81 mm) and thinner polymer coating (7.6 mm), in conjunction with improved biocompatibility of the polymer, everolimus-eluting stents may favorably affect neoointimal hyperplasia. The PRECOMBAT-2 trial evaluated the safety and efficacy of PCI using everolimus-eluting Xience V stents (Abbott Corp.) for patients with left main stenosis. The outcomes were presented by Dr. Park SJ. They assessed 334 consecutive patients who received everolimus-eluting stents for left main stenosis between 2009 and 2010. The 18-month incidence rates of major adverse cardiac or cerebrovascular events, including death, myocardial infarction, stroke or ischemia-driven target vessel revascularization, were compared with those of PRECOMBAT randomized study comparing patients who received sirolimus-eluting stents (N=327) or coronary artery bypass grafts (N=272). Everolimus-eluting stents (8.9%) showed a comparable incidence of major adverse cardiac or cerebrovascular events as sirolimus-eluting stents (10.8%); adjusted hazard ratio of everolimus-eluting stents, 0.84; 95% confidence interval, 0.51-1.40; p=0.51) and CABG (6.7%, HR, 1.40; 95% CI, 0.78-2.54; p=0.26). The composite incidence of death, MI or stroke also did not differ among patients receiving EES (3.3%), SES (3.7%; HR, 0.63; 95% CI, 0.27-1.47; p=0.29), and CABG (4.8%; HR, 0.67; 95% CI, 0.29-1.54; p=0.34). However, the incidence of ischemia-driven TVR in the EES group (6.5%) was higher than in the CABG group (2.6%, HR, 2.77; 95% CI, 1.17-6.58; p=0.02), but comparable to SES (8.2%, HR, 1.14; 95% CI, 0.64-2.06; p=0.65). Angiographic restenosis rates were similar in the SES and EES groups (13.8% vs. 9.2%, p=0.16). Dr. Park said that "this study has a limitation because of non-randomized study design. However, the outcomes of everolimus-eluting stents, as compared with the first-generation DES or CABG, indicate the safety and efficacy of new-generation DES for left main stenosis. In particular, the numerically low incidence of repeat revascularization warrants further studies to prove the efficacy of new-generation DES."

Bifurcation Summit

Dr. Bon-Kwon Koo (Seoul National University Hospital, Seoul, Korea) will present with a subject of "Why FFR and Why Not FFR in Bifurcation Lesions?" in the Bifurcation summit at 10:06. Why FFR? Angiographic evaluation alone is sometimes inaccurate and does not reflect the functional severity of lesions, especially in ostial lesions. Fractional flow reserve (FFR) is an easily obtainable lesion-specific parameter for the physiologic evaluation of epicardial coronary artery stenosis, which takes into account the interaction between the anatomic stenosis and the area of perfusion supplied by a specific coronary artery. From recent studies, it was found that 1) FFR-guided provisional side branch intervention strategy is feasible and effective, 2) angiographic evaluation overestimates the functional severity of jailed side branch lesions in every step of the provisional strategy for bifurcation lesions and 3) functional status of jailed side branch lesions after drug-eluting stent implantation does not change significantly during follow-up. These results indicate that FFR measurements in bifurcation lesions can be helpful in decision making for revascularization and can prevent unnecessary complex coronary interventions and related complications in patients with bifurcation lesions. WHY NOT FFR? FFR is not needed in all bifurcation lesions and should be carefully used in complex bifurcation lesions. The following should be fully understood before the application of FFR to the complex bifurcation lesions: 1) As the amount of ischemia is clinically more relevant than the presence of ischemia, FFR should be measured in large side branches 2) When FFR is measured for side branch lesions, the influence of proximal and distal lesions should always be considered 3) It is difficult to predict the functional significance of jailed side branch lesion based on anatomic and physiologic parameters assessed before the intervention. 4) The risk and benefit of FFR measurement should be carefully evaluated in cases of highly angulated, diffused, multiple or calcified lesions and the pressure wire should not be jailed by a stent. 5) FFR does not need to be measured in side branches with TIMI flow or severe dissection. 6) As the lesions included in most of previous studies were relatively short ostial side branch lesions, the results of previous studies cannot be applied as they are in diffuse or multiple side branch lesions. 7) In cases of side branch stenting, high side branch FFR does not always guarantee excellent results.

Figure. A case example which shows the discrepancy between the results of anatomic evaluations and fractional flow reserve. LAD; left anterior descending coronary artery, IVUS; intravascular ultrasound, MLD; minimum lumen diameter, MLA; minimum lumen area, FFR; fractional flow reserve.
Best reliable brand of the total nitrate without Tolerance Problems

For individualized treatment of all stages of CHD and heart failure.

Further new aspects for the treatment of:
- glaucoma
- peripheral occlusive vascular disease
- portal hypertension
- chronic obstructive respiratory disorders
- perioperative blood pressure control (solution)
- acute pulmonary oedema (solution)
Adnan Kastrati, MD (Deutsches Herzzentrum, Technische Universität, Munich, Germany) will give a lecture about periprocedural antithrombotic therapy during PCI with the results of the ISAR-REACT trial. He focused on the results of ISAR-REACT 4, which was recently published in the New England Journal of Medicine. The direct thrombin inhibitor bivalirudin protects patients with NSTEMI from severe adverse events as well as a combination of abciximab and unfractionated heparin following PCI while reducing major bleeding. The data suggests that bivalirudin might be the preferred drug for patients undergoing PCI for an acute MI, with or without ST-segment elevation. They studied 1,721 patients with NSTEMI who had been pre-treated with 600 mg of clopidogrel prior to PCI. Patients were randomized to 70 U/kg bolus of heparin plus abciximab in a 0.25 mg/kg bolus followed by an infusion of 0.125 μg/kg/min for 12 hours (n=861) or bivalirudin in a bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/hr (n=860) for the duration of PCI. The primary endpoint of severe adverse events (death, any recurrent MI, urgent TVR, or major bleeding) was identical for both groups at 30 days at 10.9% in the abciximab group and 11.0% in the bivalirudin group (RR 0.99; 95% CI 0.74-1.32; P=0.94) (Figure 1). The cumulative incidence of death, any MI, and urgent TVR was also identical at 12.8% with abciximab and 13.4% with bivalirudin (RR 0.96; 95% CI 0.74-1.25; P=0.76). The individual component endpoints of death (1.4% with abciximab and 1.6% with bivalirudin), MI (12.0% vs. 11.4%), and any urgent TVR (0.8% vs. 1.3%), were all equivalent between arms. Major bleeding, meanwhile, was more frequent with abciximab (4.7% vs. 2.6%; RR 1.38; 95% CI 1.10-1.70; P=0.02) (Figure 2). They defined major bleeding as intracranial, intraocular, or retroperitoneal, Hb decrease >40g/L plus either overt bleeding or need for transfusion of 2 or more units, which was a very rigorous definition of serious bleeding. This result suggests the findings of HORIZONS-AMI, a prospective, open-label, randomized, multicenter trial that compared the direct thrombin inhibitor to heparin plus abciximab in 3,602 patients undergoing primary PCI. Abciximab and unfractionated heparin, as compared with bivalirudin, failed to reduce the rate of the primary endpoint and increased the risk of bleeding among patients with NSTEMI undergoing PCI.

**Imaging & Physiology Workshop**

### In-Stent Neoatherosclerosis: A Final Common Pathway of Late Stent Failure

Soo-Jin Kang, MD (Asan Medical Center, Seoul, Korea) will talk about 'Neoartherosclerosis' as a mechanism of late stent failure including stent restenosis and very late stent thrombosis. In-stent restenosis (ISR) is generally considered to be a stable process, however, recent studies have reported that one third of patients with ISR are presented with acute coronary syndromes. Furthermore, there is emerging histological and angiographic evidence of late de novo in-stent neoatherosclerosis. They performed optical coherence tomography and grayscale and virtual histology intravascular ultrasound in 50 patients (70 stable, 20 unstable angina) with 50 DES in-stent restenosis lesions and intimal hyperplasia/50% of stent area over 32.2 months. OCT findings indicating in-stent neoatherosclerosis (Figure 1) were frequently identified in patients with DES-ISR, especially late DES-ISR, including TCFAs-containing intima in 52%, intimal rupture in 58%, and thrombi in 58%. Irrespective of clinical presentations of DES-ISR (unstable or stable angina), 90% of the lesions had lipid-containing neointima (Figure 2). Even in stable angina patients, one third showed TCFAs-containing intima and half had in-stent intimal rupture. Neointimal fibrous cap thickness decreased over time, with a follow-up duration 120 months being the best cut-off value to predict the presence of TCFAs-containing intima. All of these findings suggest that neoatherosclerotic neointimal degenerative changes over time or neoahterosclerosis superimposed on a stable neointimal platform, consistent with our recent data using VH-IVUS analysis. Furthermore, VH subgroup analysis in the current study supported OCT findings in that the presence of VH-defined TCFAs-containing neoatherosclerosis of NC was related to the longer follow-up duration. This study demonstrates in-stent TCFAs-containing neoatherosclerosis, neoatherosclerosis, and thrombi in DES failure patients presenting with ISR (whether stable or unstable). These findings suggest that in-stent neoatherosclerosis assessed by OCT and VH-IVUS may be an important mechanism of DES failure, especially late after implantation.

---

**Figure 1.** Optical coherence tomography findings of neointima inside DES

A, intimal rupture (red arrow); B, TCFAs-containing neointima surrounded by signal-poor lipidic area (red arrow); C, fibrotic neointima with microvessels (red arrow); D, Intraluminal red thrombus with fast attenuation (red arrow); E, TCFAs-containing neointima (red arrow) with lipidic tissue; F, intimal rupture (red arrow) surrounded by TCFAs-containing neointima.
The State of the Art Lecture: Non-Invasive Imaging

Thursday, April 26, Art Room, Level 4, 5:00 PM – 6:00 PM

Computed FFR: What Is the Final Goal?

Recently, coronary artery angiography (CCTA) of 64-detector rows or greater has emerged as a novel non-invasive imaging modality that is capable of providing high-resolution non-invasive images of coronary artery lesions. While CCTA demonstrates good diagnostic performance for detection and exclusion of anatomic coronary artery stenoses, numerous prior studies have revealed an unreliable relationship between detection of obstructive anatomic coronary artery stenoses detected by CCTA and hemodynamically significant (HD-significant) coronary artery disease (CAD), as detected by reduced myocardial perfusion or coronary blood flow by myocardial perfusion SPECT or fractional flow reserve (FFR), respectively. Similarly, a non-negligible minority of individuals have been identified to possess HD-significant CAD; specifically CCTA anatomic assessment demonstrated angiographically mild (50%) maximal per-patient stenosis. These findings emphasize the need for additional measures beyond anatomic stenosis severity for the detection and exclusion of HD-significant CAD. Measurement of FFR during invasive cardiac catheterization represents the "gold standard" for assessment of the hemodynamic significance of coronary artery lesions by determination of the integrity of blood flow proximal and distal to coronary stenoses. FFR evaluation of anatomic coronary stenosis reveals a similarly unreliable relationship of anatomic coronary artery stenosis severity by quantitative coronary angiography (QCA) of coronary artery blood flow. These findings have important clinical implications, as FFR-guided coronary revascularization in contrast to anatomic angiographic-guided coronary revascularization improves long-term clinical outcomes of patients with CAD.

At present, there are no non-invasive cardiac tests capable of simultaneous determination of both anatomic coronary artery stenosis severity and the hemodynamic significance of the observed coronary artery stenosis. HeartFlow, Inc. (‘HeartFlow’) has developed a non-invasive method to compute FFR (cFFR) from patient-specific CCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. Preliminary results in patients suggest that non-invasive cFFR accurately predicts the hemodynamic significance of coronary lesions when compared to directly-measured FFR during cardiac catheterization (figure).

Perfusion CT: Can It Replace the MRI?

The current management of symptomatic patients with suspected coronary artery disease (CAD) frequently begins with attempts to detect coronary stenosis causing a myocardial perfusion defect by using nuclear isotopic techniques. The identification of such lesions generally leads to invasive coronary angiography for further documentation of vessel stenosis, anatomic characterization, and suitability for catheter-based intervention or surgery if clinically indicated. More recently, the advent of CT angiography suggests that the option of beginning the workup of younger patients with suspected CAD with an anatomic-based study, instead of a test designed to look at myocardial perfusion, makes a lot of sense. Indeed, the possibility of coupling anatomic and functional information in 1 single test tailored to the needs of specific patients could have important implications for the evaluation of CAD clinically.

Initial subclinical studies documenting the possibility of translating these methods to humans indicate that the combination of coronary angiograms with measurements of relative differences in myocardial blood flow during stress are feasible with current 64-slice multidetector computed tomography (MDCT) technology. Previous work using CMR to measure myocardial perfusion suggests that most of the needed information is provided by the stress images. However, differentiation between stress-induced perfusion defects and myocardial scars such as old infarcts or myocardial fibrosis secondary to previous myocardial damage or due to other disease processes, hampers the use of stress studies only. Thus, baseline studies at rest are crucial for the full implementation of this technology. In this regard, the main obstacle for its full implementation has been the magnitude of radiation that would be needed for the acquisition of myocardial perfusion information not only during stress, but also at rest using current 64-row MDCT technology with retrospective gating.

Recent developments in MDCT technology that would allow for prospective gating during 64-row MDCT or for complete myocardial imaging during 1 gantry rotation have created the possibility of reducing radiation exposure enough to enable the performance of combined angiography and myocardial perfusion assessment at rest and during stress. It is feasible to perform both studies with current techniques and a total of 8 to 10 millievents. Moreover, if the coronary angiogram provides the complete diagnostic picture, the cardiologist could elect not to perform a perfusion study. Based on current studies of patients with suspected coronary artery disease, we estimate that perfusion imaging would be required in only 25% to 30% of cases, depending on the type of population being studied. Such techniques would be ideal for the assessment of the patient with chest pain and history of advanced disease, expected to have calcified coronaries or previously placed coronary stents. It is possible that the addition of perfusion information to the angiographic study would increase the test sensitivity to flow-limiting lesions and facilitate the indication for revascularization procedures even for patients without extensively calcified arteries or coronary stents, based on the combination of anatomic plus functional information.

Considering the fast pace of progression of MDCT technology, it is reasonable to speculate that, indeed, the future may be closer than previously anticipated. Dr. Gudrun Feuchtner (Professor, Innsbruck Medical University) will cover the recent development of perfusion CT technology and clinical trials in the Tutorial Arena.
April 23-26, 2013, Seoul, Korea
The Convention Center, Sheraton Grand Walkerhill Hotel

18TH ANGIOPLASTY SUMMIT
TCTAP 2013
TRANSCATHETER CARDIOVASCULAR THERAPEUTICS ASIA PACIFIC
**Moderate Oral Abstract Competition**

**Abstract Zone, Level B2, 2:00 PM - 6:00 PM**

"Moderate Oral Abstract Completion" will be held on April 25th (Wednesday), 2:00 - 6:00 PM and on April 26, 8:30 - 12:30 AM and 2:00 - 6:00 PM, at the Abstract Zone I & II (Level B2). Lots of diligent researchers will show their new results of several major topics- AMI,ACS, Pharmacological Treatment, Imaging, Structural Heart Disease, Complex PCI, DES, and Endovascular Intervention. After four or five presentations on each topic, panelists will select the best oral abstract and hand out an award. This year, sixty abstracts were selected among abstracts submitted from about 20 countries. Before the actual presentations, we will introduce some interesting abstracts. In the “Acute Myocardial Infarction/Acute Coronary Syndrome I” session at 2:00 PM on April 25, Dr. Brian Noronha from UK will show the result that the risk of GI bleeding is substantially lower in ST-Elevation Myocardial Infarction patients. In the “Acute Myocardial Infarction/Acute Coronary Syndrome II” session at 3:00 PM, Dr. Soon Jun Hong from Korea will present about Enoxaparin in NSTEMI patients. In the "Acute Myocardial Infarction/Acute Coronary Syndrome II" session at 3:00 PM, Dr. Soon Jun Hong from Korea will present about "Cardiovascular Event Rates during the Four-Year Follow-Up of CTO intervention from all over the world including Asia, America and Europe. During the CTO intervention, the interventionist might meet hurdles and difficulties for the opening of totally occluded segment. There have been tremendous developments in devices and techniques for the CTO intervention, but we still have some hesitations for the opening of CTO lesion because of the lack of confidence and other numerous reasons. Dr. Barry D. Rutherford (Saint Luke’s Hospital, USA) will present the case for the aggressive approach to patients with CTO lesions. Dr. Nicolaus J. Reifart will review the changes in strategy and outcomes in Europe. Two very skilled experts in CTO intervention from Japan, Dr. Yasushi Asakura (Toyohashi Heart Center) and Dr. Toshiya Muramatsu (Saiseikai Eastern Hospital), will provide the optimal solution for management of problems and complications during the intervention. Both have performed numerous cases of CTO lesions in Japan and other nations as an invited operator. Many audience members can expect a nice response from the difficulties of the success and learn from them as an indirect experience. Same with the last several years, this ANGIOPLASTY SUMMIT TCTAP-2012 will also hold the CTO forum, which was made by collaborating with the Japanese CTO club and the CCT. This meeting will cover pathology with imaging to intervention via antegrade and retrograde. Dr. Satoru Sumitsuji (Nozaki Tokushukai Hospital, Nagoya Tokushukai General Hospital) will present the fundamental wire

**What’s Going On in Chronic Total Occlusion during ANGIOPLASTY SUMMIT TCTAP 2012?**

**Thursday, April 26, Coronary Arena, Mugunghwa Hall 1, Level 1, 3:00 PM - 5:00 PM**

1. **Breakfast meeting, “Techniques for CTO intervention – Stay Calm, Be Confident!”**, Thursday, AM 7:00 - 8:00 in the Coronary Arena
2. **CTO Forum in Collaboration with Japanese CTO club and CCT (Complex Cardiovascular Therapeutics)**, Thursday, PM 3:00 in the Coronary Arena
3. **Amazing CTO Intervention LIVE transmission from Toyohashi Heart Center, Japan, Thursday, 1) 3:00 PM in the Main Arena (Vista Hall, Level B2), 2) 4:00 PM in the Coronary Arena (Mugunghwa Hall 1, Level 1)**

The special lectures and live case demonstrations with world renowned experts in the field of CTO will provide participants with the latest information on techniques and devices for their daily interventional practice.

- Learn the advanced techniques and device selection for chronic total occlusions to optimize procedural success.
- Update on the state-of-the-art techniques, technology and new devices.
- Review the clinical indications and evidence for chronic total occlusion intervention.

First, during the breakfast meeting we will meet the experts of CTO intervention from all over the world including Asia, America and Europe. During the CTO intervention, the interventionist might meet hurdles and difficulties for the opening of totally occluded segment. There have been tremendous developments in devices and techniques for the CTO intervention, but we...
Clinical Research Coordinating Center (CRCC)

Data Management
Improve essential information to prevent and control cardiovascular disease through analysis without bias
- Statistical Analyses
- Data Safety Monitoring Boards (DSMB)
- Publicized Research Studies

Core Laboratories
Providing the result of an unbiased interpretation about pharmaceutical or mechanical intervention in coronary artery disease and cardiac transplant studies
- Quantitative Coronary Angiographic (QCA) Core Laboratory
- Intravascular Ultrasound (IVUS) Core Laboratory
- OCT/VH-IVUS Imaging Center

Conference

ANGIOPLASTY SUMMIT-TCTAP
- Focusing on Evidence-based Medicine in Interventional Cardiovascular Medicine
- Live Cases, Late Breaking Clinical Trials, Scientific Symposia, Practical Workshops, Case Reviews, Abstracts, Exhibitions, and much more
- Presentations on Innovative Devices and Future Therapies

IMAGING & PHYSIOLOGY SUMMIT
- Live Case Demonstrations related to Imaging & Physiology
- Expanded Basic Image Interpretation Workshop for IVUS & VH-IVUS, OCT, and FFR
- Clinical State-of-the-Art Lectures
- Challenging Case Competitions with the Experts

CHRONIC TOTAL OCCLUSION LIVE
- Invited Operators from Japan
- Live Case Demonstrations: Advanced Operator’s Techniques & Novel Devices
- Case Presentations & Reviews: Interactive Discussions with Experts and Q&A
- Special Lectures: Technical Tips & Tricks to Optimize Procedural Success

TRANSCATHETER AORTIC VALVE IMPLANTATION SUMMIT
- Live Cases Demonstrations: TAVI from “A to Z” by Pioneers in this Emerging Technology Field
- Special Lectures on All about TAVI and Good Practice of Team Work
- Case Based Learning by Experts’ Real Case Presentation

Education

Online Learning Site: www.summitMD.com
- Case Based Presentations
- State-of-the-art Lectures
- Live Interviews with World Renowned Experts

Fellowship Training Program
- Short-term & Long-term Training Program

ACT Program (Asan Medical Center Interventional Cardiology Training Program)
Left Main Intensive Course | FFR&IVUS Guided PCI
- Exclusive Training program for Small Group (Max. 12 attendees)
- Interact & Discuss with Operators during the Procedure
- Learn from Evidence-Based Medicine
- Special Lectures from Experts on Left Main, CTO, DES, Clinical Data Management
- Hands-on Experience as a Second Operator

Fundraising

“Leading to Greatness for the Better Human Life”
Fundraising and donations will be used to improve survival rate and quality of life for patients with heart disease.

Contact Information:
Tel. 82-2-3010-7254
E-mail: cvrfund@summitmd.com
New DES

Coronary Arena, Mugunghwa Hall 1, Level 1, Coronary Session 5, 5:00 – 6:00 PM.

Second-generation DES

The PLATINUM (A Prospective, Randomized Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent) was a fairly large randomized clinical trial of 2 DES, the Promus everolimus-eluting stent vs the Promus Element stent. They use the same drug and same polymer, and same elution kinetics, but there is a different stent platform with the Element stent having a platinum-enriched and perhaps more visible stent and some other property advantages that have been promoted. These DES trials have shown very low rates at 1 year of TLF. To be fair, it seems like these data that we have seen from Promus Element, Resolute, and even some of the Xience V data are still supportive of using these stents in clinical practice. Dr. Gregg W. Stone will present the lecture "Lessons from the pooled data using Xience Everolimus-eluting stent". The "Results of Resolute series of studies" will be reviewed by Dr. Martin B. Leon in succession. The RESOLUTE (A Randomized Comparison of a Zotarolimus-Eluting Stent with an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) all-comers 2-year trial data has demonstrated a rather shorter duration of CTO lesion, longer-term occlusion has much calcium deposition without microchannels, but shorter chronic total occlusion that has organized thrombus with microchannels in original lumen area with some calcification (arrowhead) in dense fibrous tissue. (Figure 1)

The wire manipulation is more difficult with longer-term occlusion in spec of histopathological characteristics. During the antegrade approach, once the wire migrated into the subintimal space, the wire easily advances into the subintimal space; yet it is difficult to cross to the distal true lumen because of lower resistance to advance into subintimal space coupled with increased resistance to traversing the plaque (Figure 2). During the retrograde approach, antegrade subintimal tracking (dotted line) and retrograde subintimal tracking (solid line), even though the angiogram shows that the 2 wires are separated (antegrade and retrograde), both wires can be positioned in the same subintimal space. After the retrograde wire comes into the same lumen with the antegrade wire, crossing into the doors of the cath lab went into the trial, so there was a very high rate of accruement. What was interesting was that the target lesion failure, which is the primary endpoint, was absolutely superimposable for those two.

Bioabsorbable Stents

The 4-year results of the LEADERS trial showed a statistically significant separation in late stent thrombosis with the biolimus A9 drug on a polyactic acid polymer. The EVOLVE trial used the Synergy™ stent and they looked at Synergy and Synergy half-dose against the Promus Element™ stent. This is PLGA (copoloy lactic acid/glycolic acid), adluminally directed, 3- to 5-micron thickness polymer releasing everolimus in the same dose as the everolimus in the Promus, Xience V™ and the Platinum Element stent. Synergy had incredibly low late losses that were consistent and non-inferior to the Promus Element stent. The Promus Element stent in this trial had a late loss of 0.15 mm ± 0.34 mm. We saw 0.1 mm ± 0.26 mm in the full-dose arm and 0.13 mm ± 0.25 mm in the half-dose arm and there were no differences in clinical events. So the EVOLVE trial suggested that you could actually deliver the same amount of drug and get the same surrogate response in terms of late loss without having the polymer there for a long time. PLGA of 3-5 microns thick is gone in 4 months. Another interesting trial was the NEXT. NEXT used a new stent that has a well on the external surface of the stent and it has no polymer at all. It just has an excipient to release sirolimus. This trial showed late loss of 0.14 mm +/- about 0.26 mm for all of the patients and it showed that same sort of late loss even in the diabetic patients. There were at least 40 diabetic patients in the small study. The ABSORB data in about a hundred patients with a bioresorbable stent showed recovery of endothelial function at 1 year for these patients. These patients are obviously highly scrutinized because of the promise around this bioresorbable stent. The outcomes with TLF rates of 3.0%-4.0% are the best outcomes which are observed with DES today. It is a combination of technique or the adjunctive pharmacology, but it is going to be a real challenge for new stents with bioresorbable...
from page 21

polymers or bioresorbable stents to
demonstrate even noninferiority. A
noninferiority trial with a TLF rate of 2.5% is
going to require 9000 patients. In the “New DES”
session, Dr. Stephen G. Ellis will
review the data about these interesting
stents under the title of “Bioabsorbable
DES” session, Dr. Stephen G. Ellis will
demonstrate even noninferiority. A
polymers or bioresorbable stents to

DESI in Diabetes

Patients with diabetes are especially prone
to restenosis after stenting, making drug-
eluting stents (DES) preferable to bare metal
stents (BMS) in this patient population.

Whether next-generation DES will improve
outcomes compared with first-generation
DES is an area of ongoing research and
controversy. There are some data showing
that the second-generation stents are better
than the first-generation stents, but it’s not
that clear cut. We have some conflicting
data. For example, the SIRTAx-LATE trial
showed that the Cypher stent is better than the Taxus in diabetics; this was first-
generation versus first-generation. On the
other hand, we have this huge meta-
analysis of the SPIRIT trial (Clinical Trial
of the Xience V Everolimus Eluting
Coronary Stent System) and the comparison of the
Everolimus-eluting Xience-V Stent with the
Paclitaxel-eluting Taxus Liberté Stent
(COMPARE) trial showing no difference
between the Xience V and Taxus stent in
patients with diabetes; the data is
somewhat confusing. The SORT-OUT IV
showed a trend that the Xience V stent is
superior to the Cypher stent in diabetic
patients, but it’s a subgroup analysis,
again. To solve the controversial data,
we need a randomized trial that specifically
addresses diabetes. In India, a new
prospective randomized trial has been
launched, which is called the TUXEDO trial
(Taxus Element vs Xience-V in a Diabetic
Population). The trial has diabetes as
an inclusion criterion and they have a primary
clinical endpoint (cardiac death, MI and TVR
at 12 months). You can check on the
progress of the TUXEDO from Dr. Upendra
Kaul, principle investigator of the trial at the

“New DES” session.

Is there any evidence to show that there’s
any difference in how the new-generation
stents behave in diabetes? The data on the
diabetic subgroup (1500 patients) of the
pooled resolute trials showed that there is
no difference, at least between 2 second-
generation DES (the Xience V and the
Resolute stent) in diabetic patients.

Drug Eluting Balloons

The drug eluting balloons (DEB) are another
innovation in interventional cardiology.

The rationale of using DEB is based on the
concept that with highly lipophilic drugs,
even short contact times between the bal-
loon and the vessel wall are sufficient for
effective drug delivery. Using a paclitaxel-
eluting balloon, 3 RCTs have targeted in-
stent restenosis (ISR) following BMS
implantation: PACCOCATH-I, II and PEP-
CAD-II. Recently, Long-term follow-up data
from the 108 patients in the PACCOCATH-I
and II showed that the bene-
fit of treating ISR with a
paclitaxel-coated balloon is
sustained over the long-term
(5-years). 4 DEBs have pro-
vided clinical data for ISR
after BMS and DES: DIOR-II,
In.Pact Falcon, Pantera Lux
and SeQuent Please. All
these 4 DEBs seem to have a
single digit number of TLR rates within the
first 9 to 12 months after PCI of BMS-ISR.
However, the TLR rates after PCI of DES-ISR
seem to be generally higher. The current
guidelines recommend DEB only for ISR
of BMS. However, many interventional cardi-
ologists expect something beyond the
guidelines. The THUNDER trial with drug-
eluting balloons in the femoropopliteal
arteries showed improved short-term
patency rates compared with plain balloon angi-
oplasty. Dr. Juan F. Granada
will present the “Re-
Emergence of Local Drug Delivery: Challenge
and Opportunities” in the last lecture of this
session. He will review several trials and
show the clinical role of the DEB in coro-
nary and peripheral therapy, it is expected
that he will demonstrate the evolving tech-
nology and possibilities of the DEB.

Structural Heart Disease Symposium

Endovascular Arena, Level 1, Mugunghwa Hall 2, 2:00 PM – 6:00 PM

Mitral Valve Treatment

Future therapies of percu-
taneous treatment for
mitral regurgitation and
the evolving role of the
MitraClip system (Abbott
Vascular) were presented
in the symposium as first action. The
MitraClip system is the first device that is
“truly nonsurgical” and the one that is fur-
thest along in terms of testing and clinical
application, Chuck Simonton, MD, said. It
recapitulates the surgical procedure by fix-
ing the two free mitral edges together to
create a double orifice. Surgery has pro-
vided proof of principle that this strategy
yields durable results. Thus far, about
2,000 patients worldwide have been treat-
ed with the MitraClip in both registries and
randomized trials. A registry analysis from
the EVEREST II study cohort showed that
percutaneous repair of mitral regurgitation
(MR) in high-risk patients reduced MR and
improved clinical symptoms. However,
outside experts cautioned that due to a
number of limitations in the study, the
results, though positive, should only be
viewed as providing impetus for a more
definitive trial. EVEREST II randomized 279
patients with moderate to severe MR and
anatomical criteria suitable for endovas-
cular repair to percutaneous treatment with
the MitraClip (n=184) or surgery
(n=95) in 2:1 ratio. The results revealed that
the primary efficacy endpoints of free-
dom from death, valve reoperation, and 3
or 4 grade MR favored surgery. However,
MitraClip therapy was safe and resulted in
improvements in quality of life according
to the New York Heart Association’s func-
tional classification, showing it was as
good as or better than surgery. Maurice
Buchbinder, MD thinks that the data we’ve
got available is very encouraging and
there is more optimistic data expected to
be presented within the next 12 months.
There is some clinical experience with
other mitral technologies, such as coro-
nary sinus annuloplasty devices, Dr.
Buchbinder said. They have been slow to
come into clinical use because of
technical issues of delivering a
device to the coronary sinus as
well as concerns about mechani-
ical integrity. Recently, however,
encouraging data have emerged
from the TITAN trial showing a
reduction in mitral regurgitation
severity and improvements in left ventricular function and exer-
cise capacity out to 1 year with
the Carillon Mitral Contour
System (Cardiac Dimensions). The main
limitation of this approach is that the
sinus crosses the circumflex in a signifi-
cant proportion of patients. Also on the
horizon are a number of novel approach-
es. For example, one device anchors a bal-
loon-like catheter in the left ventricular
apex, filling the space of the regurgit-
ating orifice. This has the attraction of being

Continued on page 23
procedurally simple. Also in preclinical development are replacement technologies. However, these devices face formidable challenges, including large size and difficulty anchoring them in the mitral orifice. “The steps we have taken in mitral valve therapy are really giant steps because it is a new field,” moderator, David E. Kandzari, MD, concluded.

Renal Denervation
Catheter-based renal denervation by radiofrequency ablation results in substantial and sustained blood pressure reduction without serious adverse events in patients with refractory hypertension. A first-in-man trial was reported at the annual American College of Cardiology meeting in March 2009; a randomized trial was presented at the American Heart Association Scientific Sessions 2010 and published simultaneously in the Lancet. Horst Sievert, MD, emphasized its efficacy and safety in patients with resistant, very-difficult to control hypertension, and suggested this treatment would become part of more general care for severe hypertension.

Renal denervation not only reduces resistant hypertension but also decreases left ventricular mass and improves diastolic function in patients with hypertensive heart disease, according to a new analysis stemming from the Symplicity HTN-2 trial. Renal denervation’s positive effect on LV hypertrophy is “a big plus” for renal denervation David E. Kandzari, MD said, pointing to the results of the LIFE trial comparing a beta blocker with an angiotensin receptor blocker in patients with hypertension and LV hypertrophy. Renal denervation may be especially useful for patients with diastolic heart failure, because the patients have a big, thick heart that doesn’t relax normally in diastole, although contractile function is okay. Dr. Kandzari also cautioned that renal denervation requires further validation, even though the results we have seen so far are positive.

ASD Closure
Ostium secundum atrial septal defect (ASD) is one of the most common congenital heart diseases (CHDs) and accounts for the majority of CHD in adults. During the last decade, there has been a remarkable change in the treatment strategy of ASD, shifting the therapeutic gold standard from surgery to transcatheter closure, along with refinements and evolvement of device technology. The reports on the outcome of transcatheter ASD closure have shown an excellent efficacy as well as a low complication rate. However, the procedural details and/or outcomes of this “usually straightforward” procedure may be influenced by several factors including morphologic characteristics of the defect, comorbid disease, as well as individual factors including age and the weight of the patient. Since the risk-benefit relationship in both the very young and the elderly subsets of the patients has not been clearly defined yet, closure of an ASD with a device may be subtracted from the treatment option in these patient groups.

Jae Young Choi, MD presented the issue relating age and device closure of ASD. He reviewed current evidences relevant to age issue in the treatment of ASD and presented data from his own institute. In the registry cohort, 754 patients were treated by transcatheter technique using Amplatzer septal occluder (ASO) and 223 patients treated by surgery. Among the transcatheter closure group, 79 were small children or infants weighing 10kg or less, 48 were elderly patients aged 60 years or more, and the remaining 627 were aged in between. Comparing the 3 subgroups in terms of safety and efficacy of the procedure, none of the subgroups appeared to have significant difference, except for the more frequent switching of treatment modality to surgery in smaller subgroup and more frequent incidence of pneumonia hypertensive and atrial arrhythmia in the elderly subgroup.

Dr. Choi suggested further modification in design for smaller ASO is warranted toward appropriate waist-diameter to rim-width ratio to facilitate suitability of device closure in smaller patients with less room for a larger device. He also said “elderly patients with comorbidity such as pulmonary hypertensive, atrial arrhythmia, myocardial dysfunction or ischemic heart disease needs meticulously planned strategy, taking into account all treatment options for an optimal treatment outcome”. He concluded that transcatheter closure of ASD is a viable option in the wide age spectrum with comparable safety and efficacy to standard age group.